CADD Administration Sets with Flow Stop 의 안전성 경고

Department of Health에 따르면, 해당 안전성 경고 는 Hong Kong 에서 Smiths Medical 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 날짜
    2016-05-10
  • 사례 출판 날짜
    2016-05-10
  • 사례 국가
  • 사례 출처
    DH
  • 사례 출처 URL
  • 비고 / 경고
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • 데이터 추가 비고
    Medical Device Safety Alert
  • 원인
    Medical device safety alert: smiths medical cadd administration sets with flow stop medical device manufacturer, smiths medical, has issued a medical device safety alert concerning its cadd administration sets with flow stop. the following products re-order numbers for devices with a device expiration date on or before march 2021 are affected: 21-7321-01, 21-7321-24, 21-7322-01, 21-7322-24, 21-7323-24, 21-7324-01, 21-7324-24, 21-7333-24, 21-7336-01, 21-7336-24, 21-7339-01, 21-7339-24, 21-7359-01, 21-7359-24, 21-7383-01, 21-7383-24, 21-7390-01, 21-7390-24, 21-7391-01, 21-7391-24, 21-7394-01, 21-7394-24, 21-7395-24]. the affected products have the potential to impact flow rate when used with a variety of cadd ambulatory infusion pumps. this may result in under delivery of medication. the manufacturer’s test data indicates that under infusion has the potential to contribute to an average of an additional 5.2% under delivery beyond the +/- 6% stated in the operator’s manual for the cadd pumps. the manufacturer’s risk analysis identified the following possible serious adverse health consequences with a very remote probability of occurrence: 1) inadequate symptom control (dependent on therapy being delivered). for example: increase in pain or increase in cardiac symptoms (heart rate, rhythm, blood pressure); 2) inadequate treatment (dependent on therapy being delivered). for example: subtherapeutic doses delivered of medication in which a specific volume needs to be infused such as antibiotics, chemotherapy, or nutritional therapy. the manufacturer concluded that there is a very remote probability that under delivery may occur resulting in patient harm, as all possible levels of patient harm were evaluated to be rare. the manufacturer is not requesting return of product. the manufacture advises users to continue to monitor for under delivery when utilising the cadd administration sets with flow stop. according to the manufacturer, the affected products are distributed in hong kong. if you are in possession of the affected products, please contact your supplier for necessary actions. posted on 10 may 2016.

Device

  • 모델명 / 제조번호(시리얼번호)
  • 제품 설명
    Medical Device Safety Alert: Smiths Medical CADD Administration Sets with Flow Stop Free
  • Manufacturer

Manufacturer